Delos Wealth Advisors’s Bioventus BVS Stock Holding History

Delos Wealth Advisors’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-43	Closed	-$1K	–	274
2021 Q4	$1K	Buy	+43	New	+$611	﹤0.01%	402

Other funds holding BVS

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Nuance Investments Kansas City, Missouri $717M AUM 3.8% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Delos Wealth Advisors's BVS Position: Q1 2022 in Review

Delos Wealth Advisors sold out of Bioventus (BVS) in Q1 2022, closing a stake of 43 shares — an estimated $1K sold.

Delos Wealth Advisors first reported a position in BVS in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 105 funds tracked by Wall St. Rank hold BVS as of Q1 2022.

Delos Wealth Advisors reported no remaining Bioventus position as of Q1 2022 after selling out during the quarter.
Delos Wealth Advisors sold 43 Bioventus shares in Q1 2022, an estimated $1K.
Delos Wealth Advisors first reported a position in Bioventus in Q4 2021 and held it in 1 quarter.
Delos Wealth Advisors's Bioventus position peaked at $1K in Q4 2021.
105 funds tracked by Wall St. Rank held Bioventus as of Q1 2022.

Based on Delos Wealth Advisors's 13F filing for Q1 2022, filed 16 May 2022.